MAGE-A12 Activators
MAGE-A12 belongs to the Melanoma Antigen Gene (MAGE) family, a group of proteins known for their expression in various types of cancer and limited presence in normal tissues. The MAGE family members, including MAGE-A12, are classified as cancer/testis antigens due to their predominant expression in male germ line cells and various malignant cells. MAGE-A12 plays a crucial role in regulating cellular processes that are pivotal for cancer development and progression, such as cell cycle regulation, apoptosis, and the immune response evasion. Its function is closely tied to its ability to interact with other proteins within the cell, acting as part of complexes that modulate key signaling pathways involved in tumorigenesis. The precise role of MAGE-A12 in normal physiology remains less understood, but its overexpression in cancer cells suggests an involvement in the pathological processes that confer growth advantage, resistance to cell death, and metastatic capabilities to cancer cells.
The activation of MAGE-A12, like other cancer/testis antigens, is intricately linked to epigenetic modifications and transcriptional regulation that are aberrant in cancer cells. The promoter regions of MAGE family genes, including MAGE-A12, are typically methylated in normal tissues, leading to their silencing. However, in cancer cells, demethylation of these promoter regions occurs, resulting in the gene's activation and expression. This epigenetic change is a hallmark of many cancer types and is thought to be induced by various factors, including the cellular microenvironment, oncogenic signaling pathways, and the global changes in DNA methylation patterns characteristic of malignancies. Additionally, the activation of MAGE-A12 can be influenced by stress responses within the tumor microenvironment, such as hypoxia, which can further promote the expression of cancer/testis antigens.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
A cytidine analog that incorporates into DNA and RNA, inhibiting DNA methyltransferase, thereby leading to demethylation of DNA and reactivation of silenced genes, including MAGEA family genes. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
A 5-Aza-2′-Deoxycytidine analog used to demethylate DNA, which can result in the re-expression of epigenetically silenced genes, such as MAGEA genes, in the context of cancer. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A hydroxamic acid that inhibits histone deacetylases (HDACs), allowing for a more open chromatin structure and potential reactivation of silenced genes including those of the MAGEA family. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
An HDAC inhibitor that, by changing chromatin structure and modifying gene expression, can lead to the upregulation of various genes, possibly including MAGEA genes. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Another HDAC inhibitor that induces changes in gene expression patterns and can lead to the activation of previously silenced genes, which may include the MAGEA gene family. | ||||||